Plasma cell leukemia
Drug research and approvals for plasma cell leukemia: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 140 studies of plasma cell leukemia are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 140
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- Phase 1 Study of 6MW5311 in Adults With Relapsed or Refractory Blood CancersNCT07914556 · Phase 1 · Mabwell (Shanghai) Bioscience Co., Ltd. · starts Sep 16, 2026
- The Value of a Tailored-based, Exercise Program for Improving Quality of Life of Patients With Hematologic…NCT07912684 · Not applicable · Gruppo Italiano Malattie EMatologiche dell'Adulto · starts Nov 10, 2026
- QLS4131 Plus Isatuximab in Newly Diagnosed Primary Plasma Cell LeukemiaNCT07903623 · Phase 2 · Institute of Hematology & Blood Diseases Hospital, China · starts Oct 25, 2026
- Low-dose Liposomal Amphotericin B for Antifungal Prophylaxis in Prolonged Neutropenia PatientsNCT07763054 · Not reported · Haikou Affiliated Hospital of Central South University Xiangya School of Medicine · starts Aug 1, 2025
- Development and Dissemination of Exercise Prescription and Intervention for Cancer PopulationsNCT07751783 · Not applicable · Kaohsiung Medical University Chung-Ho Memorial Hospital · starts Mar 12, 2026
- Clinical and Biological Cohort Study of EBV-Positive T/NK-Cell Lymphoproliferative DiseasesNCT07727083 · Not reported · Rong Tao · starts Aug 11, 2026
- Rutgers University Study of the Genetics of Blood CancersNCT07714044 · Not reported · Rutgers, The State University of New Jersey · starts Sep 22, 2026
- CM336 Plus Isa-VR in Newly Diagnosed Primary Plasma Cell LeukemiaNCT07652905 · Phase 2 · Institute of Hematology & Blood Diseases Hospital, China · starts Sep 15, 2026
- Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness LevelNCT07649525 · Phase 3 · University of Leeds · starts Jul 3, 2026
Phase 2 10
- LenalidomideCRL4(CRBN) E3 ubiquitin ligase inhibitor
- DexamethasoneGlucocorticoid receptor agonist
- Bortezomib26S proteasome inhibitor
- BusulfanDNA inhibitor
- DaratumumabLymphocyte differentiation antigen CD38 inhibitor
- DoxorubicinDNA topoisomerase II alpha inhibitor
- PanobinostatHistone deacetylase inhibitor
- PomalidomideCRL4(CRBN) E3 ubiquitin ligase inhibitor
- GemcitabineRibonucleoside-diphosphate reductase RR1 inhibitor
- ElotuzumabSLAM family member 7 inhibitor
Phase 1 or earlier 12 of 14
- TacrolimusFK506-binding protein 1A inhibitor
- FilgrastimGranulocyte colony stimulating factor receptor agonist
- FilanesibKinesin-like protein 1 inhibitor
- CytarabineDNA inhibitor
- MethotrexateDihydrofolate reductase inhibitor
- SirolimusFK506-binding protein 1A inhibitor
- CarmustineGlutathione reductase inhibitor
- PaliferminFibroblast growth factor receptor 2 agonist
- Carfilzomib26S proteasome inhibitor
- SargramostimGranulocyte-macrophage colony-stimulating factor receptor agonist
- BendamustineDNA inhibitor
- CyclophosphamideDNA inhibitor
How its trials ended
52 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 7 whose ending is known, 29% met their primary endpoint, 0% missed it and 71% stopped early.
- Ongoing2752%
- Completed, result not reported1325%
- Status unknown510%
- Stopped: other or unclear48%
- Met its primary endpoint24%
- Stopped: enrollment or feasibility12%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA